更新于：2024-11-21

Cannabidiol

大麻二酚

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol、(−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol、(−)-trans-cannabidiol

+ [48]

靶点

作用机制

CB拮抗剂(大麻素受体拮抗剂)

治疗领域

肿瘤神经系统疾病遗传病与畸形+ [8]

在研适应症

结节性硬化症Dravet综合征Lennox-Gastaut综合征+ [29]

非在研适应症

寻常痤疮急性移植物抗宿主病良性基础型眼睑痉挛+ [17]

原研机构

中南大学Apurano Pharmaceuticals GmbH德义制药有限公司

+ [1]

在研机构

Northwell Health, Inc.

Zynerba Pharmaceuticals, Inc.Jazz Pharmaceuticals Ireland Ltd.

+ [20]

非在研机构

Benuvia Therapeutics, Inc.

Botanix Pharmaceuticals Ltd.Radius Pharmaceuticals, Inc.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2018-06-25),

Dravet综合征Lennox-Gastaut综合征癫痫发作

最高研发阶段(中国)临床前

特殊审评罕见儿科疾病 (美国)、孤儿药 (欧盟)、优先审评 (澳大利亚)、快速通道 (美国)

登录后查看时间轴

结构

分子式C21H30O2

InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N

CAS号13956-29-1

关联

456

项与大麻二酚相关的临床试验

NCT06362889 / Not yet recruiting临床1期

An Exploratory Study to Evaluate the Safety and Efficacy of Microneedling With Cannabidiol (CBD) and Hempseed Oil for Treating Acne Vulgaris

This is a prospective, single center, open label study to assess the safety and effectiveness of microneedling with CBD and hempseed oil for the treatment of moderate to severe acne in adults 22-years of age or older.The objective of this exploratory study is to evaluate the safety and efficacy of HealMD's CBD with hempseed oil to reduce the appearance of moderate to severe facial acne.

开始日期2025-12-01

申办/合作机构

REJUVA MEDICAL AESTHETICS, INC.初创企业

[+1]

ACTRN12624001303538 / Not yet recruiting临床3期

The efficacy of cannabidiol adjunct to standard treatment in reducing positive psychotic symptoms in young people with first episode psychosis

开始日期2025-03-01

申办/合作机构-

NCT06686914 / Not yet recruiting临床1期IIT

The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex

The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.

开始日期2025-02-01

申办/合作机构

West Virginia University

[+1]

100 项与大麻二酚相关的临床结果

登录后查看更多信息

100 项与大麻二酚相关的转化医学

登录后查看更多信息

100 项与大麻二酚相关的专利（医药）

登录后查看更多信息

6,914

项与大麻二酚相关的文献（医药）

2025-02-01·European Neuropsychopharmacology

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

Review

作者: Groenink, Lucianne ; Batalla, Albert ; van der Meer, Pim B. ; van der Meer, Pim B ; Cammà, Guido ; Verdouw, Monika P. ; Verdouw, Monika P

Interest in cannabinoids' therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids' therapeutic potential in psychiatric disorders. 22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8-THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9-THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

2025-02-01·CNS & Neurological Disorders - Drug Targets

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Article

作者: Quaranta, Loreta ; Bianco, Ciro ; Placidi, Fabio ; Di Mauro, Giovanni ; Castelli, Alessandro ; De Angelis, Viviana ; Leonardis, Francesca ; Vietri, Giovanni ; Liguori, Claudio ; Celeste, Maria Grazia ; Mercuri, Nicola Biagio ; Pagano, Andrea ; Izzi, Francesca

Introduction:Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment for these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex.Case Presentation:Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.Conclusion:According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

2025-02-01·Neurochemical Research

Cannabidiol Plays a Modulatory Function on the Methamphetamine-Induced Reward Through Hippocampal D2-Like Dopamine Receptors

Article

作者: Mohammadi, Mahsa ; Haghparast, Abbas ; Omidiani, Seyed Erfan ; Azizbeigi, Ronak

Methamphetamine (METH), a stimulant that is extremely addictive, directly affects the central nervous system. METH's abuse and consumption are directly linked to mental illnesses, psychosis, and behavioral and cognitive impairments. It may disrupt the reward system and dopaminergic transmission. METH's rewarding qualities are associated with a rise in dopamine. Additionally, cannabidiol (CBD), one of the primary cannabinoid components of the cannabis plant, significantly affects dopaminergic transmission and may aid in reward- and addiction-related behaviors. To shed light on the role of the D2-like dopamine receptor (D2R) in the hippocampal dentate gyrus (DG), the present study examined the effects of CBD on the acquisition and expression of the conditioned place preference (CPP) induced by METH. The function of D2R was ascertained by delivering Sulpiride microinjections, as a D2R antagonist Sulpiride (0.25, 1, and 4 μg/0.5 μL DMSO12%) into the DG. Moreover, an intracerebroventricular injection of CBD at a dose of 10 μg/5 μL for CPP acquisition and 50 μg/5 μL for CPP expression was given to rats. According to the current research, CBD dramatically reduced the acquisition and expression of CPP resulting from METH. However, Sulpiride suppressed the effect of CBD on METH-induced CPP acquisition and expression, with a greater impact on expression experiments. Ultimately, this study proposed that the expression experiment of METH-induced CPP appears to be heavily dependent on D2R in the DG.

721

项与大麻二酚相关的新闻（医药）

2024-11-18

·GlobeNewswire-Health Care

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, will be presenting at the 7th Cannabinoid-Derived Drug Development Summit. The event will take place November 18-20, 2024, at the Wyndham Beacon Hill Hotel in Boston, MA. Key data from Artelo’s development programs will be highlighted in three separate sessions titled: Fatty Acid-Binding Protein 5 (FABP5) Inhibitors as Novel Therapeutics (featuring ART26.12)ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer CachexiaART12.11: A Novel Cannabidiol Cocrystal Demonstrating a Pharmacokinetic Profile Comparable to Epidiolex® in Rats “We are delighted to share the results of our work from three innovative approaches to endocannabinoid and lipid modification,” said Professor O’Sullivan. “These presentations provide an opportunity to explore business development and collaboration with academic and industrial researchers. Our clinical and preclinical pipeline exemplifies how lipid modification can lead to the development of distinct and differentiated product candidates addressing serious medical conditions with limited treatment options.” For event registration, please visit: https://cannabinoid-derived-drug-development.com/take-part/register/ About ART27.13ART27.13 is a highly potent, peripherally restricted new chemical entity, targeting CB1 and CB2 receptors, with the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer cachexia patients. Originally developed by AstraZeneca plc, ART27.13 has been in clinical studies with over 250 subjects. A statistically significant and dose-dependent increase in body weight was observed in patients with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Having completed a Phase 1 study in cancer patients where ART27.13 demonstrated an excellent safety profile, Artelo is now advancing it in the CAReS trial as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Currently, there is no FDA-approved treatment for cancer anorexia cachexia syndrome. About ART26.12ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) is the first selective FABP5 inhibitor to be cleared by FDA to initiate first-in-human studies. ART26.12 is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN). Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About ART12.11ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

临床1期

2024-11-18

·药时代

一款减肥药撤市之后

正文共：2386字 1图预计阅读时间：5分钟由于患者招募困难，卫材终止了一项三期临床试验。美东时间2024年11月17日，知名行业媒体《Endpoints News》发文称，卫材终止了旗下Lorcaserin（氯卡色林）用于辅助治疗Dravet综合征的三期MOMENTUM 1研究（NCT04572243）。根据美国临床试验数据库（ClinicalTrials.gov）查询，目前MOMENTUM 1研究已处于终止状态，并提示该状态并非由于任何安全性或有效性原因导致。关于Dravet综合征 Dravet综合征（Dravet syndrome ，DS），为婴儿期起病的难治性癫痫综合征，由法国医生Charlotte Dravet在1978年首次报道，既往又称婴儿严重肌阵挛癫痫。 DS是一种罕见的癫痫性脑病，根据国外文献报道DS患病率为1/40000~1/20000（也有文献报道为发病率为1/15700~1/40900）占3岁以内婴幼儿癫痫的8%。2018年，该疾病被列入国家第一批罕见病目录（编号：105号）。 DS发病主要由遗传因素决定，其主要致病基因为钠离子通道α1亚单位基因SCN1A突变，此外如SCN1B、GABRG2等基因也可能与Dravet综合征有关。目前，DS暂无治愈方法，治疗主要是对症支持治疗，旨在减少癫痫发作的频率和强度。常用药物包括丙戊酸、司替戊醇、芬氟拉明、药用级大麻二酚、托吡酯等。其中，芬氟拉明作为一种5-HT2C受体激动剂，最早（1973年）被批准用于减肥，1997年因严重心脏毒性而停用。后来其较低剂量被重新启用，治疗一些癫痫性脑病：2020 年，美国和欧盟先后批准芬氟拉明作为DS治疗的添加药物。相同命运的氯卡色林此次，卫材终止的氯卡色林与芬氟拉明同为5-羟色胺（5-HT，又称血清素）受体激动剂。其研发历程也颇为相似。氯卡色林原研为Arena，2012年获FDA批准上市用于减肥治疗，商品名Belviq。后因市场表现一般，Arena于2017年将其权益卖给了卫材。值得一提的是，基于芬氟拉明的前车之鉴。FDA在批准Belviq时要求生产商开展一项随机、双盲、安慰剂对照的上市后研究，以评估氯卡色林的心血管风险。这项研究有12000例参与者，为期5年，于2018年6月结束。因此，氯卡色林是完成FDA要求的长期心脏安全研究的第一种新型减肥药物。只不过，FDA在对其安全性数据进行审查时发现，服用氯卡色林的患者被确诊为癌症的人数更多（462， 7.7% vs 423, 7.1%）。 2020年1月，FDA要求Belviq，Belviq XR从美国市场撤市。这对卫材而言，称得上无妄之灾。尽管癌症风险增高的原因还不明确，FDA也无法断定氯卡色林就是直接的致癌原因，但撤市已成定局。后者激流勇进，前者寸步难行芬氟拉明在肥胖症失利之后，在癫痫性脑病中“复活”。那么氯卡色林，理应也可走通这条路径。 2020年，卫材在与FDA协商后启动了氯卡色林治疗DS的三期MOMENTUM 1研究。当时目标是在美国招募58名受试者，如今4年过去，卫材还在招募在面临招募困境。根据《Endpoints News》报道，卫材一位的发言人通过电子邮件表示，“随着其他经FDA批准的疗法可用于治疗这一复杂的疾病（DS），招募患者进行试验性治疗变得极其困难。” 目前，针对DS的治疗涌现了各种新型治疗方式，包括但不限于：Stoke的反义寡核苷酸（ASO），STK-001；Longboard的5-HT2C受体超激动剂Bexicaserin；Encoded的AAV9介导的候选基因调控疗法，ETX101。其中，Bexicaserin已进入临床三期阶段。它虽然与氯卡色林、芬氟拉明同为5-HT2C受体激动剂，但却显示出对5-HT2C受体的选择性增加。具体而言，5-HT2受体次家族有A、B、C三种亚型，研究发现，中枢5-羟色胺主要通过作用于脑内5-羟色胺2C受体（5-HT2C）起到调节食欲的作用，这也是其减重的原因。而5-HT2A与5-HT2B激动，可能导致致幻活性与心脏毒性相关不良反应。芬氟拉明与右芬氟拉明的退市，便与同时激动5-HT2B导致的肺动脉高压和心脏瓣膜异常有关。至于氯卡色林，今年4月是我国列入第二类精神药品目录。此前（2013年），该药物已被FDA列入《管制物质法案》附表Ⅳ管理。以目前的科研水平结合当前商业价值，几经波折的氯卡色林，或许不值得继续投入资源。参考资料： 1.Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges（Endpoints News） 2.clinicaltrials.gov 3.Dravet 综合征诊断与治疗的中国专家共识（癫痫杂志） 4.Wirrell E C, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel[J]. Pediatric Neurology,2017,68:18-34 5.田小娟，张月华. Dravet综合征治疗和预后研究进展[J]. 中国实用儿科杂志,2017(10):789-793 6.新列管药“氯卡色林”的由来（中国禁毒报） 7.其他公开资料封面图来源：pixabay 主管说没有预算，这个局怎么破？这里可以24小时免费观看FDA、EMA培训录像，自己不断成长，还不麻烦公司！~ 2024-11-17 第四届佛山创新药论坛圆满落幕，行业领袖共绘“BD出海与投融资”新未来 2024-11-16 FDA要变天！特朗普正式提名罗伯特·肯尼迪领导卫生与公众服务部 2024-11-15 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩！

2024-11-14

·GlobeNewswire-Health Care

Avicanna Reports Q3 2024

9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3 2024. “We are pleased to report the results of another quarter showing progressive improvements across our four business pillars. Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model.” stated Aras Azadian, CEO at Avicanna Inc. Financial highlights: Revenue of $6.3 million and $18.8 million for the three- and nine-month period ending September 30, 2024, representing a 0.34% and 75% increase over the three- and nine-month period ended September 30, 2023, respectively.Improved consolidated gross margin percentage to 57% during Q3 2024, from 46% for the same period in 2023.Growth in gross profit of $3.7 million and $9.5 million, respectively, for the three- and nine month period ended September 30, 2024, compared to $2.9 million and $4.9 million for the same periods in 2023, an increase of 25% and 91%, respectively.Narrowed adjusted EBITDA loss for the three- and nine-month period ended September 30, 2024, narrowed to $293,931 and $719,347, respectively, a 38% and 76% decrease from an adjusted EBITDA loss of $473,650 and $3 million, respectively, in the corresponding periods last year.Fully repaid outstanding principle balance of approximately $1,300,000 owed under non-convertible debenture. Other highlights: The United States Patent and Trademark Office granted the Company a Patent, Patent No. US 20230025693A1, covering deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.The Company completed Q3 2024 with 35 commercial SKUs and 136 commercial listings. The Company sold approximately 45,126 and 144,756 units, for the three- and nine-month period ended September 30, 2024, respectively, compared to 31,887 and 118,265 compared to the same periods in 2023. This represents an increase of 42% and 22% growth in total finished goods sold, respectively. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing a various forms high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1191556-7e71-4d8d-b5d7-4bc0f5db4d6a

财报

100 项与大麻二酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10915	大麻二酚	N03AX24	DB09061

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结节性硬化症	美国	Jazz Pharmaceuticals UK Ltd.	2020-07-31
Dravet综合征	美国	Jazz Pharmaceuticals UK Ltd.	2018-06-25
Lennox-Gastaut综合征	美国	Jazz Pharmaceuticals UK Ltd.	2018-06-25
癫痫发作	美国	Jazz Pharmaceuticals UK Ltd.	2018-06-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
婴儿痉挛	临床3期	波兰	Jazz Pharmaceuticals Plc	2017-04-24
婴儿痉挛	临床3期	美国	Jazz Pharmaceuticals Plc	2017-04-24
Dravet综合征	临床3期	日本	Jazz Pharmaceuticals Plc	-
脆性X综合征	临床3期	-	Harmony Biosciences LLC	-
Lennox-Gastaut综合征	临床3期	日本	Jazz Pharmaceuticals Plc	-
癫痫发作	临床3期	日本	Jazz Pharmaceuticals Plc	-
结节性硬化症	临床3期	日本	Jazz Pharmaceuticals Plc	-
Rett综合征	临床前	英国	Jazz Pharmaceuticals Plc	2019-07-29
婴儿痉挛	临床前	波兰	Jazz Pharmaceuticals Plc	2017-04-24
婴儿痉挛	临床前	美国	Jazz Pharmaceuticals Plc	2017-04-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04760613 (CTgov)	临床1/2期	疼痛障碍 \| 根性疼痛 \| 椎间盘疾病	14	cannabidiol (Cannabidiol (CBD))	簾糧鹽齋製窪範齋網夢(鹹積衊襯鑰蓋鹹積鹽鹽) = 獵廠壓襯網鏇醖選淵鑰襯蓋襯鏇簾糧願鏇顧衊 (製鬱蓋廠顧鬱蓋蓋鏇餘, 構憲廠夢網網獵鑰鬱壓 ~ 鏇壓鹹糧醖鹹遞願蓋築) 更多	-	2024-09-19
NCT04760613 (CTgov)	临床1/2期	疼痛障碍 \| 根性疼痛 \| 椎间盘疾病	14	Placebo (Placebo (PCB))	簾糧鹽齋製窪範齋網夢(鹹積衊襯鑰蓋鹹積鹽鹽) = 顧遞蓋壓衊艱遞築蓋壓襯蓋襯鏇簾糧願鏇顧衊 (製鬱蓋廠顧鬱蓋蓋鏇餘, 顧鑰製醖製鹹鑰製蓋窪 ~ 製淵鑰鬱積繭鏇積襯鹹) 更多	-	2024-09-19
NCT04286594 (CTgov)	临床2期	焦虑症	15	CBD	廠憲鹹簾顧鹽觸餘餘憲(製範繭遞艱鑰廠鑰鏇製) = 築積鑰襯鹽繭顧製觸醖顧遞壓網構鹹憲鬱簾繭 (範齋鏇廠網壓窪艱壓窪, 觸艱廠艱願蓋範製夢鹹 ~ 廠醖餘醖製鹹簾製鏇憲) 更多	-	2024-08-27
NEWS 人工标引	临床3期	癫痫发作	-	cannabidiol	(顧憲選鹹窪廠齋艱醖鹽) = The study failed to achieve its primary endpoint of a pre-specified percentage change in indication-associated seizure frequency during the 16-week treatment period compared to baseline. 製窪衊製夢築窪窪蓋餘 (範鬱觸觸廠觸衊積蓋夢 ) 未达到	不佳	2024-08-23
NCT03582137 (CTgov)	临床2期	帕金森病	74	cannabidiol (CBD Cannabis Extract Oral Solution)	範襯遞壓網醖鹽齋膚觸(蓋衊網襯蓋蓋蓋鹹憲繭) = 鬱範簾夢艱網醖築窪願構廠願壓遞糧顧選範糧 (壓艱構築齋遞齋積窪製, 鹽糧積艱廠範顧願範廠 ~ 製簾廠願廠築鬱艱襯壓) 更多	-	2024-07-23
NCT03582137 (CTgov)	临床2期	帕金森病	74	Placebo (Placebo)	範襯遞壓網醖鹽齋膚觸(蓋衊網襯蓋蓋蓋鹹憲繭) = 夢齋鏇齋壓憲夢糧構蓋構廠願壓遞糧顧選範糧 (壓艱構築齋遞齋積窪製, 構範夢廠積鏇窪淵鹽淵 ~ 糧廠願積簾簾鹽遞簾鬱) 更多	-	2024-07-23
NCT03900923 (CTgov)	临床2期	自闭症谱系障碍	29	CBD (3 mg/kg 98% Pure CBD)	廠獵蓋築蓋築襯膚範鹽(襯憲遞鑰範遞醖膚鏇糧) = 製遞齋積壓鹽艱醖餘膚衊網顧獵窪繭觸窪餘遞 (網齋簾蓋構範築遞壓遞, 艱範襯鑰鹹廠網艱醖鹹 ~ 鏇膚膚糧鏇壓構艱醖壓) 更多	-	2024-05-31
NCT03900923 (CTgov)	临床2期	自闭症谱系障碍	29	CBD (6 mg/kg 98% Pure CBD)	廠獵蓋築蓋築襯膚範鹽(襯憲遞鑰範遞醖膚鏇糧) = 齋廠壓鹽憲顧鏇願窪選衊網顧獵窪繭觸窪餘遞 (網齋簾蓋構範築遞壓遞, 膚膚壓壓鏇觸築願壓獵 ~ 鹹齋鏇餘願襯齋鑰獵淵) 更多	-	2024-05-31
NCT04754399 (ASCO2024) 人工标引	临床2期	关节痛 \| HR阳性乳腺癌	39	CBD (Epidiolex)	(築繭築範鹽蓋廠顧獵窪) = 廠構鏇願鑰積醖衊齋廠遞繭糧願顧簾膚獵餘壓 (製積鹹獵鬱積醖築網淵 ) 更多	积极	2024-05-24
DDW2024	N/A	食管活动障碍	-	10 mg CBD	觸顧簾鏇選壓壓窪鹽願(鑰積壓願選糧糧艱顧壓) = 窪網鑰壓鏇鹽鬱鬱衊餘鹽餘憲繭範糧糧獵網醖 (鏇網範製遞鏇簾網廠繭 )	-	2024-05-21
DDW2024	N/A	食管活动障碍	-	10 mg CBD	艱鏇遞築構簾醖膚鑰願(憲製製顧範獵餘製膚憲) = 夢窪糧鬱憲選膚夢蓋夢遞衊齋夢製選夢餘鏇積 (鹽積構網簾積醖糧繭積 )	-	2024-05-21
DDW2024	N/A	食管活动障碍	-	10 mg CBD	網齋鏇蓋鹽淵製襯糧鹽(艱範餘構蓋齋艱網齋夢) = 鹽鹽齋衊繭淵鬱壓醖製製鹹鬱壓構積壓鑰艱餘 (獵鏇廠簾蓋願鹽夢廠齋 )	-	2024-05-21
DDW2024	N/A	食管活动障碍	-	10 mg CBD	醖簾糧鑰鹽範膚衊築觸(網築範餘繭簾夢蓋製夢) = 繭蓋廠蓋窪選鹽製積觸簾糧鏇廠衊餘積餘築簾 (衊襯窪繭觸蓋艱範遞鏇 ) 更多	-	2024-05-21
DDW2024	N/A	食管活动障碍	-	20 mg CBD	醖簾糧鑰鹽範膚衊築觸(網築範餘繭簾夢蓋製夢) = 築積壓網憲選蓋構憲製簾糧鏇廠衊餘積餘築簾 (衊襯窪繭觸蓋艱範遞鏇 )	-	2024-05-21